A Multicenter, Open-label, Phase 2 Study of Imprime PGG and Pembrolizumab in Subjects With Advanced Melanoma Failing Front-line Treatment with Checkpoint Inhibitors (CPI) or Triple Negative Breast Cancer (TNBC) Failing Front-line Chemotherapy for Metastatic Disease

January 19, 2018
https://clinicaltrials.gov/ct2/show/NCT02981303
Cancer - Breast, Cancer - Melanoma
Principal Investigator: Haythem Y Ali, MD
Advanced Melanoma, Triple Negative Breast Cancer, Breast cancer
Accepting Participants